Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127050951 | 12705095 | 1 | I | 20131126 | 20140630 | 20160831 | 20160831 | EXP | FR-ASTRAZENECA-2014SE47902 | ASTRAZENECA | 47.00 | YR | F | Y | 0.00000 | 20160901 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127050951 | 12705095 | 1 | PS | IRESSA | GEFITINIB | 1 | Oral | 8000 | MG | N | U | 206995 | 250 | MG | TABLET | QD | |||
| 127050951 | 12705095 | 2 | SS | TARCEVA | ERLOTINIB HYDROCHLORIDE | 1 | Oral | N | U | 0 | 150 | MG | QD | ||||||
| 127050951 | 12705095 | 3 | C | INEXIUM | ESOMEPRAZOLE | 1 | Oral | 40.0MG UNKNOWN | 0 | 40 | MG | ||||||||
| 127050951 | 12705095 | 4 | C | OXYCONTIN | OXYCODONE HYDROCHLORIDE | 1 | Oral | 80.0MG UNKNOWN | 0 | 80 | MG | ||||||||
| 127050951 | 12705095 | 5 | C | OXYNORM | OXYCODONE HYDROCHLORIDE | 1 | Oral | 20.0MG UNKNOWN | 0 | 20 | MG | ||||||||
| 127050951 | 12705095 | 6 | C | SOPHIDONE | HYDROMORPHONE HYDROCHLORIDE | 1 | Oral | 24.0MG UNKNOWN | 0 | 24 | MG | ||||||||
| 127050951 | 12705095 | 7 | C | PECFENT | FENTANYL CITRATE | 1 | 100.0UG UNKNOWN | 0 | 100 | UG | |||||||||
| 127050951 | 12705095 | 8 | C | RELISTOR | METHYLNALTREXONE BROMIDE | 1 | 12MG/0.6ML | 0 | |||||||||||
| 127050951 | 12705095 | 9 | C | PRIMPERAN | METOCLOPRAMIDE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127050951 | 12705095 | 10 | C | TOLEXINE | DOXYCYCLINE | 1 | 0 | ||||||||||||
| 127050951 | 12705095 | 11 | C | CISPLATINE | CISPLATIN | 1 | 0 | ||||||||||||
| 127050951 | 12705095 | 12 | C | ALIMTA | PEMETREXED DISODIUM | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127050951 | 12705095 | 1 | Lung adenocarcinoma |
| 127050951 | 12705095 | 2 | Lung adenocarcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127050951 | 12705095 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127050951 | 12705095 | Abdominal pain | |
| 127050951 | 12705095 | Arthralgia | |
| 127050951 | 12705095 | Dermatitis acneiform | |
| 127050951 | 12705095 | Malignant neoplasm progression |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127050951 | 12705095 | 1 | 20131026 | 20140415 | 0 | |
| 127050951 | 12705095 | 2 | 20140416 | 2014 | 0 | |
| 127050951 | 12705095 | 4 | 20160809 | 0 | ||
| 127050951 | 12705095 | 10 | 20140530 | 0 | ||
| 127050951 | 12705095 | 11 | 20131002 | 0 | ||
| 127050951 | 12705095 | 12 | 20131002 | 0 |